article thumbnail

National variation in ASCVD risk between Pooled Cohort Equations and PREVENT [Cardiovascular disease]

Annals of Family Medicine

Study Design and Analysis This study utilized data from NHANES 2011-2019 to calculate two ASCVD risk scores for each eligible individual: one using the race-based PCE and the other using the race-agnostic PREVENT equation. Each individual was separated into clinically significant risk categories of <7.5%, 7.5-10%,

article thumbnail

Diabetes related complications among Ethiopian Jews-Outcomes of a 10 years cohort study in Israel [Population health and epidemiology]

Annals of Family Medicine

Multivariate analyses were conducted to evaluate adjusted hazard ratios for various demographic, clinical, and comorbid factors at the onset of the disease and after a 10-year follow-up period. Population: Jewish CHS members, aged 18+, diagnosed with T2D between 2000-2011, born in Israel or Ethiopia.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Episode 148: Antiracism in Medicine Series Episode 4 – Dismantling Race-Based Medicine Part 2: Clinical Perspectives

The Clinical Problem Solvers

Nwamaka Eneanya and Jennifer Tsai to discuss the limitations and harms of race-based medicine in clinical practice. Our guests explain how we can incorporate race-conscious medicine in clinical settings, medical education, and biomedical/epidemiological research to responsibly recognize and address the harms of racial inequality.

Clinic 52
article thumbnail

Using technology to reclaim our time

Today's Hospitalist

Yet this expansion has come with a significant administrative burden, particularly that of clinical documentation. This isn’t about replacing your clinical judgment. Ambient dictation, or ambient clinical documentation, represents a paradigm shift. This isn’t about replacing your clinical judgment. The result?

article thumbnail

No Sleep ‘Til District Court: Jazz Sues FDA Over Sodium Oxybate Clinical Superiority Determination

FDA Law Blog

This time, rather than use codes and patent certifications, the fight is over orphan drug exclusivity (“ODE”), with Jazz challenging FDA’s clinical superiority decision concerning sodium oxybate in the treatment of narcolepsy. 360cc(c), the statute does not permit FDA to promulgate regulations to use clinical superiority to break ODE.

Clinic 52
article thumbnail

OTAT Town Hall on Cell Therapy CMC – The Recording is Available but Here’s an Appetizer

FDA Law Blog

The next town hall will focus on the clinical development of gene therapy products for rare diseases in February 2023. The Agency stated that the most common reason for a clinical hold of a Phase 1 study under an investigational new drug (IND) is related to safety. Common CMC Issues for Phase 1 IND Study. Comparability.

article thumbnail

510(k) Modernization 2023

FDA Law Blog

In 2011, the Institute of Medicine released a report recommending elimination of the 510(k) process altogether ( link ), noting an inherent conflict between the legislative framework and FDA’s stated goals to protect patients and promote innovation in support of public health.

Medical 64